BACKGROUND
Development of resistance of Plasmodium falciparum is an increasing problem for antimalarial chemotherapy because resistance against most available drugs, especially chloroquine and pyrimethamine-sulfadoxine (SP), has developed in the majority of world-wide parasite populations [1] . Therefore, several strategies to counteract resistancedevelopment are in place as the use of combined therapies with artemisinin derivatives but identification of new natural compounds remains essential.
Founded in 1997, Millenia Hope Inc ® , a small biotech company based in Montreal obtained an Italian patent four years ago for a natural compound called "vocamine", derived from the roots and barks of the Brazilian plant Peschiera fuchsiaefolia, a source of traditional remedies against fever. Since several years, this company has developed the extract into a new antimalarial drug named MALAREX ® . Though Millenia Hope Inc ® may not understand the drug's mechanism of action of this drug, the company does claim to have demonstrated, in vitro as well as in animals and humans, the drug's ability to kill the malaria parasite Plasmodium falciparum, and to do so safely [2, 3] . The most recent study, published by Ramanitrahasimbola et al. [4] , confirms that the alkaloid has some effect on malarial parasites both in cell cultures and mice. Only one clinical trial of this antimalarial drug conducted in Yaoundé (Cameroon) 
METHODS

Study Area
This study was carried out between January and March 2005 in Gobongo, an urban health centre located in the northern Bangui, the capital of the Central African Republic (CAR).
Bangui is located beside Oubangui river in the heart of the Central Africa, north of Democratic Republic of the Congo (Geographic coordinates 7 00 N, 21 00 E). The climate is tropical and rainfall peaks from April to November. The average temperature varies from 19 to 32°C. Plasmodium transmission occurs all over the year with peaks at the beginning and the end of the rainy season. Malaria is hyperendemic and the main parasite responsible is Plasmodium falciparum. The parasite prevalence in children aged less than 5 years is 31.8 % [6] .
Patient Recruitment
Febrile patients aged 6 to 59 months presenting at health facilities were enrolled in the study only after receiving and uniformed consent by their parent or guardian and if the following inclusion criteria were met: axillary temperature 37.5 °C; mono-infection with P. falciparum, with parasitemia in the range of 2000-200,000 asexual parasites per microliter blood; no other cause for fever than malaria; no general danger signs (unable to sit or stand up, unable to drink or breastfeed, lethargy or unconsciousness, recent history of convulsions, persistent vomiting) or signs of severe and complicated falciparum malaria according to the definition given by WHO [5] .
For participation, patients needed to be able to attend the stipulated follow-up visits and to come to the health facility when required. Parents or guardians were interviewed by a study physician about symptoms, duration of the illness, previous antimalarial therapy and other medication. Children were examined for pallor and jaundice or any other danger sign, and their axillary temperature and weight were determined.
Treatments
Participants were treated with MMH8 ® according to Millenia Hope Inc ® recommendations with one bottle of 100 mg of powder for drinkable solution twice a day for five days. Drugs were obtained from Millenia Hope Inc ® , Montréal, Canada.
The first administration was done at the time of the consultation and repeated in case of vomiting within 30 min. The following doses were given at home after information of parents. In the case of therapeutic failure or of severe symptoms, quinine was given for seven days. In addition, paracetamol was administered on days 0 and 1.
Patient Follow-Up
Follow-up appointments were scheduled for days 1, 2, 3, 7 and 14, and consisted of physical examination and completion of a standardised form. Parents and guardians were encouraged to return to the clinic at any time if their children felt unwell. Blood was collected by finger prick on days 0, 3, 7 and 14 (used to prepare thick and thin blood smears) and whenever necessary based on clinical examination.
Patients who did not turn up on a scheduled day were visited at home. Patients were excluded from the study if : [1] they reported self-administration of antimalarial drug during the follow-up, [2] they withdrew consent, [3] a concomitant disease occurred that would interfere with the evaluation of treatment efficacy, [4] the patient moved out of the follow-up area. In any other condition, patients who did not turn up on a critical day or were not seen at home were considered lost to follow-up.
Laboratory Tests
Finger prick samples collected on day 0 were used to prepare thick and thin blood films. The smears were stained with 4 % Giemsa for 20 min. Parasite density was calculated by counting the number of asexual parasites per 200 white blood cells (WBC), and adjusting for 8000 WBC per microliter. Thin blood smears were also examined for other Plasmodium spp. An adverse event was defined as an unexpected change in the baseline situation, whether or not that change was associated with the study drug.
Outcome Measures
Statistical Analysis
Efficacy data were assessed on intention to treat (ITT) analysis that included all patients who enrolled in the study. Qualitative variables were compared by using either the test or Fisher's exact test, and quantitative variables were compared by analysis of variance or the Kruskal-Wallis test. The 95% confidence intervals of percentages were calculated using the exact binomial test. The level of significance (P) was fixed at 0.05 for all statistical tests. The data were analysed using the Epi lnfo 2000 software © .
Ethical Approval
Because of lack of National Ethical Committee in CAR, this study was approved by the expert committee for the antimalarial drug policy and the Ministry of Health in CAR.
RESULTS
From January through March 2005, 51 children were enrolled, of whom 3 (5.9 %) were excluded, 6 (11.6 %) lost to follow-up, yielding 42 (82.3 %) who completed followup.
The baseline characteristics of the 42 patients followed up until day 14 are summarised in Table 1 . The overall treatment failure rate was 81 % with 51 % of ETF and 28.6 % of LTF ( Table 2) .
Among patients classified as early treatment failure (ETF), we observed: a) 8 cases (19 %) with danger signs (prostration, oedema, respiratory distress and jaundice) in the presence of parasitaemia either at day 1 (6 cases, 39.1°C of mean axillary temperature, 37134 parasites par l of mean parasitaemia density) or at day 3 (2 cases). For children with danger signs at day 1, the average increase of the parasitaemia density was significantly higher with children who did not have a previous chloroquine therapy (2.9-fold vs 1.1-fold higher, p< 0.05).. b) one children (2.4 %) with a parasitaemia at day 2, 1.3-fold higher than on day 0 and 39.3°C axillary temperature; c) six patients with a parasitaemia at day 3 with axillary temperature 37.5°C (38.3°C of mean axillary temperature). For 2 children who did not have previously a chloroquine therapy, we observed a average 1.1-fold increase of the parasitaemia density; d) seven patients (16.6 %) with a parasitaemia at day 3 25% of count of day 0. All patients did not have a previous chloroquine therapy and showed an axillary temperature < 37.5 °C. The mean increase of parasitaemia density between day 0 and day 3 was estimated to be to 2.2-fold higher.
Among patients classified as late treatment failure (LTF), we observed: a) in the Late Clinical Failure group, 6 patients (14.3%) with an axillary temperature 37.5 °C in the presence of parasitaemia either at day 7 (n = 4) or at day 8 (n = 1) or at day 12 (n = 1). Except in one case at day 7, none patients completely cleared their parasites.
b) in the Late Parasitological Failure group, parasites were not cleared at any day in 2 cases, or parasites were cleared at day 3 in 2 cases and reappeared at day 7 (n = 1) or day 14 (n = 1), or parasites were cleared at day 7 and reappeared at day 14 in 3 cases.
Among 8 patients classified as adequate clinical and parasitological response (ACPR), parasite elimination was achieved at day 3 in 3 cases (37.5 %), at day 7 in 4 cases (87.5 %) and at day 14 in one case (100%). Fever was more rapidly cleared in all cases at day 3.
There was no significant relation between therapeutic response groups and age, previous antimalarial therapy, axillary temperature or parasitaemia density at day 0.
DISCUSSION
As far as we now, this study is the first controlled clinical trial for establishing the efficacy of vocamine in the treatment of uncomplicated Plasmodium falciparum malaria in children less than five years. It is also the first clinical trial ever to have been published.
Contrarily to the claims by the Millenia Hope Company, our results confirm the doubts concerning the efficacy of this drug and its interest in the therapeutic arsenal of antimalarials available in the uncomplicated malaria treatment, as expressed by Orellana [7] and Martindale [8] .
It has been previously said that the WHO protocol 2003 is not adapted to the evaluation of new antimalarial drugs or malaria treatment for over 3 days. However, this protocol remains the best available because [1] it is the only accepted at an international level and [2] and we have ascertained its value for monitoring 7 day courses of artesunate for the treatment of uncomplicated P. falciparum malaria in nonimmune patients (European expatriates) living in Bangui (CAR) [9] .
Compared to the results of the therapeutic trials conducted in 2002-2004 in Bangui [10] , it appears that in children under five years with non-complicated malaria, the efficacy of MMH8 ® with 81% of overall treatment failure rate is far lower than that of three-day courses of chloroquine (40,9% of treatment failure rates), of amodiaquine (20% of failure rates) or of sulfadoxine-pyrimethamine association treatment (22.8% of treatment failure rates), the best therapeutic option being the association of chloroquine and sulfadoxine-pyrimethamine (7.2% of failure rates) and amodiaquine plus sulfadoxine-pyrimethamine (no failure), the last one being currently recommended by the Ministry of Health of the CAR as the first line antimalarial drug, until best therapeutic option like Artemisinin-based Combination Therapies (ACT) become available at low prices.
Thus, the paediatric formulation of MMH8 ® was ineffective in the clearance of the parasites since the majority of the treated children showed an increase of their parasitaemia densities in the days following the beginning of the treatment (except for those which had taken chloroquine before). Because of its formulation, MMH8 ® is not adapted for treatment in young children because of the volume (100 ml of drinkable solution 2 times per day) and of its unpleasant taste. Because of these pitfalls, we cannot ascertain that the administration of the product at home was regularly completed thus minimizing its apparent clinical efficacy. Nonetheless, as such an eventuality would not be the case for the majority of children, one can consider that this drug has only a limited therapeutic effect.
